Researchers found that new oral medications for obesity, specifically GLP-1 based treatments, are gaining traction among doctors. The Wegovy Pill, an oral version of semaglutide, has seen a much higher prescription rate compared to Eli Lilly’s Foundayo, another oral GLP-1 option. In the first month after its launch, 73% of primary care physicians and 78% of endocrinologists reported prescribing Wegovy Pill, while only 27% and 47%, respectively, chose Foundayo.

This is significant for anyone looking to manage their weight effectively. With obesity being a major health concern that can lead to various chronic conditions, these new oral treatments may provide a more accessible option for people who are hesitant to use injectable medications. The ease of taking a pill instead of an injection could encourage more individuals to seek treatment for weight loss, potentially leading to improved health outcomes like better cardiovascular health and increased energy levels.

The research indicates that the Wegovy Pill is outperforming Foundayo in early prescribing trends, despite Foundayo’s advantage of not requiring specific meal timing. The data comes from a snapshot of physician behavior shortly after the drugs were launched, suggesting that while Wegovy Pill is currently favored, the long-term success of both medications will depend on ongoing real-world experience and comparative effectiveness as more patients begin using them.

If you’re considering weight management options, it may be worth discussing these new oral medications with your healthcare provider. Understanding the differences between these treatments can help you make an informed choice that aligns with your lifestyle and health goals.

Source: globenewswire.com